CorMedix (CRMD) Stock Forecast & Price Target

Cormedix is viewed positively because its lead asset, DefenCath, is a first-in-class antimicrobial catheter lock solution with demonstrated safety and efficacy in the LOCK-IT-100 trial, multiple commercial supply agreements with large and mid-sized dialysis providers, and an estimated >$350M peak revenue opportunity in 2035. The outlook is further strengthened by REZZAYO’s positive Phase 3 ReSPECT results, including non-inferiority at day 90 with fungal-free survival of 61% versus 59% for SOC and a favorable tolerability profile that could support label expansion, payer acceptance, and an incremental ~$200M commercial opportunity if the prophylaxis setting is approved in 1H27 after the expected 3Q26 NDA submission. Additional upside comes from the broader platform strategy, including the acquisition of Melinta for diversified revenue streams and the ongoing TPN study for DefenCath with topline data expected in 2028, which together create multiple catalysts beyond the core U.S. DefenCath launch in 2Q24 and support continued growth despite near-term commercialization and reimbursement risks.

Cormedix is viewed negatively because, despite encouraging clinical data for DefenCath and positive signs from the 2Q26 earnings beat and a new LDO contract, the company still faces substantial uncertainty around whether the drug can gain durable traction in hemodialysis in ESRD and convert trial success into sustained commercial uptake. Its outlook remains constrained by meaningful execution risk tied to the ongoing inpatient and outpatient launches, potential dependence on favorable CMS pricing revisions and MA contracting in '27, and the possibility that a failure in DefenCath or the Melinta deal could leave the stock trading closer to the company’s net cash position with minimal pipeline value at $4/sh. Even with support from REZZAYO and an estimated ~$200M sales opportunity, the company’s single-segment U.S. concentration, commercialization dependence, and exposure to regulatory, reimbursement, competition, and deal-completion risks make the fundamental risk-reward profile unattractive.